264 related articles for article (PubMed ID: 22314534)
1. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection.
Ben-Ami R; Olshtain-Pops K; Krieger M; Oren I; Bishara J; Dan M; Wiener-Well Y; Weinberger M; Zimhony O; Chowers M; Weber G; Potasman I; Chazan B; Kassis I; Shalit I; Block C; Keller N; Kontoyiannis DP; Giladi M;
Antimicrob Agents Chemother; 2012 May; 56(5):2518-23. PubMed ID: 22314534
[TBL] [Abstract][Full Text] [Related]
2. Fluconazole-resistant Candida: collateral damage associated with prior antibacterial exposure?
Ben-Ami R; Giladi M
Future Microbiol; 2012 Sep; 7(9):1029-31. PubMed ID: 22953703
[No Abstract] [Full Text] [Related]
3. Risk factors for fluconazole-resistant candidemia.
Garnacho-Montero J; Díaz-Martín A; García-Cabrera E; Ruiz Pérez de Pipaón M; Hernández-Caballero C; Aznar-Martín J; Cisneros JM; Ortiz-Leyba C
Antimicrob Agents Chemother; 2010 Aug; 54(8):3149-54. PubMed ID: 20498325
[TBL] [Abstract][Full Text] [Related]
4. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
5. Propensity Score Analysis of the Role of Initial Antifungal Therapy in the Outcome of Candida glabrata Bloodstream Infections.
Puig-Asensio M; Fernández-Ruiz M; Aguado JM; Merino P; Lora-Pablos D; Guinea J; Martín-Dávila P; Cuenca-Estrella M; Almirante B
Antimicrob Agents Chemother; 2016 Jun; 60(6):3291-300. PubMed ID: 26976872
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of candidemia in Shiraz, southern Iran: A prospective multicenter study (2016-2018).
Arastehfar A; Yazdanpanah S; Bakhtiari M; Fang W; Pan W; Mahmoudi S; Pakshir K; Daneshnia F; Boekhout T; Ilkit M; Perlin DS; Zomorodian K; Zand F
Med Mycol; 2021 May; 59(5):422-430. PubMed ID: 32692816
[TBL] [Abstract][Full Text] [Related]
7. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy.
Magill SS; Shields C; Sears CL; Choti M; Merz WG
J Clin Microbiol; 2006 Feb; 44(2):529-35. PubMed ID: 16455909
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for fluconazole resistance in patients with Candida glabrata bloodstream infection: potential impact of control group selection on characterizing the association between previous fluconazole use and fluconazole resistance.
Lee I; Zaoutis TE; Fishman NO; Morales KH; Nachamkin I; Lautenbach E
Am J Infect Control; 2010 Aug; 38(6):456-60. PubMed ID: 20371135
[TBL] [Abstract][Full Text] [Related]
9. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp.
Playford EG; Marriott D; Nguyen Q; Chen S; Ellis D; Slavin M; Sorrell TC
Crit Care Med; 2008 Jul; 36(7):2034-9. PubMed ID: 18552700
[TBL] [Abstract][Full Text] [Related]
10. Candida glabrata: an emerging pathogen in Brazilian tertiary care hospitals.
Colombo AL; Garnica M; Aranha Camargo LF; Da Cunha CA; Bandeira AC; Borghi D; Campos T; Senna AL; Valias Didier ME; Dias VC; Nucci M
Med Mycol; 2013 Jan; 51(1):38-44. PubMed ID: 22762208
[TBL] [Abstract][Full Text] [Related]
11. Antifungal drug susceptibility, molecular basis of resistance to echinocandins and molecular epidemiology of fluconazole resistance among clinical Candida glabrata isolates in Kuwait.
Al-Baqsami ZF; Ahmad S; Khan Z
Sci Rep; 2020 Apr; 10(1):6238. PubMed ID: 32277126
[TBL] [Abstract][Full Text] [Related]
12. Distribution of fluconazole-resistant Candida bloodstream isolates among hospitals and inpatient services in Israel.
Ben-Ami R; Rahav G; Elinav H; Kassis I; Shalit I; Gottesman T; Megged O; Weinberger M; Ciobotaro P; Shitrit P; Weber G; Paz A; Miron D; Oren I; Bishara J; Block C; Keller N; Kontoyiannis DP; Giladi M;
Clin Microbiol Infect; 2013 Aug; 19(8):752-6. PubMed ID: 23005038
[TBL] [Abstract][Full Text] [Related]
13. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
[TBL] [Abstract][Full Text] [Related]
14. Epidemiological Trends of Fungemia in Greece with a Focus on Candidemia during the Recent Financial Crisis: a 10-Year Survey in a Tertiary Care Academic Hospital and Review of Literature.
Siopi M; Tarpatzi A; Kalogeropoulou E; Damianidou S; Vasilakopoulou A; Vourli S; Pournaras S; Meletiadis J
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871083
[TBL] [Abstract][Full Text] [Related]
15. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.
Pfaller MA; Castanheira M; Lockhart SR; Ahlquist AM; Messer SA; Jones RN
J Clin Microbiol; 2012 Apr; 50(4):1199-203. PubMed ID: 22278842
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and susceptibility of Nakaseomyces (formerly Candida) glabrata bloodstream isolates from hospitalised adults in South Africa.
Naicker SD; Shuping L; Zulu TG; Mpembe RS; Mhlanga M; Tsotetsi EM; Maphanga TG; Govender NP;
Med Mycol; 2023 Jun; 61(6):. PubMed ID: 37336590
[TBL] [Abstract][Full Text] [Related]
17. Antifungal resistance in patients with Candidaemia: a retrospective cohort study.
Aldardeer NF; Albar H; Al-Attas M; Eldali A; Qutub M; Hassanien A; Alraddadi B
BMC Infect Dis; 2020 Jan; 20(1):55. PubMed ID: 31952505
[TBL] [Abstract][Full Text] [Related]
18. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients.
Lortholary O; Desnos-Ollivier M; Sitbon K; Fontanet A; Bretagne S; Dromer F;
Antimicrob Agents Chemother; 2011 Feb; 55(2):532-8. PubMed ID: 21078946
[TBL] [Abstract][Full Text] [Related]
19. Impact of tolerance to fluconazole on treatment response in Candida albicans bloodstream infection.
Levinson T; Dahan A; Novikov A; Paran Y; Berman J; Ben-Ami R
Mycoses; 2021 Jan; 64(1):78-85. PubMed ID: 33000505
[TBL] [Abstract][Full Text] [Related]
20. Impact of inappropriate antifungal therapy according to current susceptibility breakpoints on Candida bloodstream infection mortality, a retrospective analysis.
González-Lara MF; Torres-González P; Cornejo-Juárez P; Velázquez-Acosta C; Martinez-Gamboa A; Rangel-Cordero A; Bobadilla-Del-Valle M; Ostrosky-Zeichner L; Ponce-de-León A; Sifuentes-Osornio J
BMC Infect Dis; 2017 Dec; 17(1):753. PubMed ID: 29212442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
